stockportfolio.pro
RPRX vs VEEV: Which Stock Is the Better Buy?
Royalty Pharma plc and Veeva Systems Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — RPRX vs VEEV, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Royalty Pharma plc (RPRX) | Veeva Systems Inc. (VEEV) | |
|---|---|---|
| Market cap | $31.6B | $31.3B |
| Revenue (latest FY) | $2.38B | $3.20B |
| Net income (latest FY) | $770.95M | $908.91M |
| Revenue growth (5y CAGR) | 2.3% | 16.9% |
| Net margin | 32.4% | 28.4% |
| Return on equity | 11.9% | 12.6% |
| P/E ratio | 28.9 | 34.1 |
| Dividend yield | 1.7% | — |
| Profitable years (of last 10) | 8 | 10 |
| Positive free cash flow | — | — |
See the full RPRX vs VEEV breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open RPRX's full financials → Open VEEV's full financials →More comparisons
Frequently asked questions
Which is bigger, RPRX or VEEV?
Royalty Pharma plc is larger by market capitalization — $31.6B versus $31.3B.
Which grows faster, RPRX or VEEV?
Over the last five fiscal years, Veeva Systems Inc. grew revenue faster — 16.9%/yr versus 2.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.